1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,450 | 1,480 | 07:46 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT THE U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE118 | 1 | HKEx | ||
| 31.12.25 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I SINGLE ASCENDING DOSE STUDY OF LAE103 | 1 | HKEx | ||
| 22.12.25 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I MULTIPLE DOSE EXPANSION STUDY OF LAE102 FOR THE TREATMENT OF OBESITY | 1 | HKEx | ||
| 15.12.25 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) IN HR+/HER2- ... | 2 | HKEx | ||
| 12.12.25 | LAEKNA-B (02105): TERMS OF REFERENCE FOR THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | 1 | HKEx | ||
| 12.12.25 | LAEKNA-B (02105): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 12.12.25 | LAEKNA-B (02105): CHANGE OF THE COMPOSITION OF THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | 1 | HKEx | ||
| LAEKNA Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | LAEKNA-B (02105): INSIDE INFORMATION EXCLUSIVE LICENSE AGREEMENT WITH QILU PHARMA FOR LAE002 (AFURESERTIB) IN THE CHINA REGION | 1 | HKEx | ||
| 29.09.25 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT POSITIVE PRELIMINARY RESULTS FROM THE PHASE I MAD STUDY LAE102 DEMONSTRATED ENCOURAGING TREND TOWARDS LEAN BODY ... | 2 | HKEx | ||
| 17.09.25 | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 17.09.25 | LAEKNA-B (02105): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 10.09.25 | LAEKNA-B (02105): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 21.08.25 | LAEKNA-B (02105): INTERIM REPORT 2025 | - | HKEx | ||
| 13.08.25 | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 31.07.25 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE103 WAS OBTAINED FROM THE U.S. FOOD AND DRUG ADMINISTRATION | 1 | HKEx | ||
| 29.07.25 | LAEKNA-B (02105): DATE OF BOARD MEETING | - | HKEx |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | 0,00 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen beim fairen Aktienwert von 50 Euro auf "Kaufen" belassen. Der Diagnostikspezialist habe seine Mittelfristziele für Wachstumstreiber... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | What Analysts Are Saying About CG Oncology Stock | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| TANGO THERAPEUTICS | 12,500 | -0,08 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
Das Unternehmen LAEKNA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,340 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAEKNA INC finden Sie auf Wallstreet Online.